Evaxion Biotech A/S ADR (EVAX) Stock Price, Quote & News

Company Profile

Evaxion A/S, a clinical-stage biotech company, develops artificial intelligence-powered immunology vaccines. The company develops EVX-01, which is in phase 2 global multi-center clinical trial for the treatment of metastatic melanoma; EVX-02, a DNA-based cancer vaccine that has completed Phase 1/2a trial to induce a therapeutic immune response in the adjuvant setting in patients with resected melanoma; and EVX-03, DNA-based cancer vaccine for the treatment of various cancers, including non-small...

Industry: Biotechnology

Sector: Healthcare

Phone: 45 31 31 97 53

Website: evaxion.ai

Address:

Dr. Neergaards Vej, 5th Floor, Horsholm, Denmark

GrowthGuruV3 Dec. 25 at 12:50 PM

$EVAX Market behavior suggests investors are rewarding credible delivery more than theoretical upside. Operating leverage needs to emerge without sacrificing balance‑sheet resilience. Successful iteration can create optionality that is not yet fully priced. Overall, the trajectory is less about vision and more about proving the operating model works.

0 · Reply

asbpame Dec. 24 at 6:03 PM

$EVAX Merry Christmas to the bulls and....ok, for the bears, also, because is Christmas

0 · Reply

asbpame Dec. 24 at 5:24 PM

$EVAX i hope Santa push the price to green in rhe last half hour...

0 · Reply

asbpame Dec. 24 at 5:04 PM

$EVAX looking at the last 1 hour bar we were about to go up, if the lines crossed gave a buy signal but the mfkers in the last minute send it down no to cross to avoid crossing upwards..

0 · Reply

CobaltCalls Dec. 24 at 11:50 AM

$EVAX Future price discovery depends on how execution velocity aligns with stated operational milestones. Execution slippage remains the dominant downside risk.

1 · Reply

asbpame Dec. 23 at 6:26 PM

$EVAX oversold

0 · Reply

baldaldo Dec. 23 at 5:48 PM

$EVAX Well crap. Now I'm wondering if the cancer vaccine is all fluff, too...

0 · Reply

Whtmtn Dec. 23 at 3:25 PM

$EVAX Déjà vu with Helen. Same sht different company.

0 · Reply

asbpame Dec. 19 at 8:37 PM

$EVAX hi guys , what fuck'n news were sent that had afected the price today? I didn't get...

2 · Reply

Manwiththeplan Dec. 19 at 8:26 PM

$EVAX well the news doesnt change much for me. The same potential

2 · Reply

Evaxion Seeks New Partner For Gonorrhea Vaccine After Merck Opts Out

Dec 19, 2025, 7:00 AM EST - 6 days ago

Evaxion provides update on MSD collaboration - retains global rights to Gonorrhea vaccine candidate EVX-B2

Dec 6, 2025, 2:00 PM EST - 18 days ago

Evaxion presents new data for EVX-04, a cancer vaccine candidate for acute myeloid leukemia at ASH Annual Meeting

Nov 12, 2025, 8:00 AM EST - 6 weeks ago

Evaxion announce 2026 financial calendar

Nov 7, 2025, 5:10 PM EST - 6 weeks ago

Evaxion presents new immune data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Nov 6, 2025, 7:56 PM EST - 6 weeks ago

Evaxion A/S (EVAX) Q3 2025 Earnings Call Transcript

Nov 6, 2025, 7:30 AM EST - 7 weeks ago

Evaxion announces business update and third quarter 2025 financial results

Nov 3, 2025, 9:00 AM EST - 7 weeks ago

Evaxion expands R&D pipeline with new AI-designed precision cancer vaccine candidate

Oct 31, 2025, 9:05 AM EDT - 7 weeks ago

Correction: Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 31, 2025, 8:00 AM EDT - 7 weeks ago

Evaxion to announce business update and third quarter 2025 financial results on November 6, 2025

Oct 30, 2025, 8:00 AM EDT - 2 months ago

Evaxion raises $7.2 million, extending cash runway to second half of 2027

Oct 27, 2025, 8:00 AM EDT - 2 months ago

Evaxion appoints Dr Helen Tayton-Martin as new Chief Executive Officer

Oct 22, 2025, 5:13 PM EDT - 2 months ago

Evaxion A/S (EVAX) Discusses 2-Year Phase II Data and AI Immunology Platform in High-Risk Melanoma Transcript

Oct 17, 2025, 8:15 AM EDT - 2 months ago

Evaxion reports 75% Objective Response Rate in phase 2 trial with AI-designed personalized cancer vaccine EVX-01

Oct 13, 2025, 8:00 AM EDT - 2 months ago

Evaxion to present a breadth of data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Oct 8, 2025, 8:12 AM EDT - 2 months ago

Evaxion expands AI-Immunology™ platform with automated vaccine design module

Oct 3, 2025, 9:00 AM EDT - 2 months ago

Evaxion to present new biomarker data for AI-designed personalized cancer vaccine EVX-01 at the SITC 2025 Annual Meeting

Sep 25, 2025, 11:07 AM EDT - 3 months ago

Evaxion A/S - Special Call

Sep 25, 2025, 7:00 AM EDT - 3 months ago

Evaxion out-licenses vaccine candidate EVX-B3 to MSD

Aug 19, 2025, 3:29 PM EDT - 4 months ago

Evaxion A/S (EVAX) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 8:00 AM EDT - 4 months ago

Evaxion to announce business update and second quarter 2025 financial results on August 14, 2025

Jul 25, 2025, 9:00 AM EDT - 5 months ago

Evaxion to present two-year clinical efficacy data from phase 2 trial with AI-designed personalized cancer vaccine EVX-01 at the ESMO Congress 2025

Jul 11, 2025, 8:00 AM EDT - 5 months ago

Evaxion finalizes agreement with EIB to convert debt into equity

Jul 1, 2025, 8:30 AM EDT - 6 months ago

Evaxion announces changes to Executive Management to optimize the value of proprietary AI-Immunology™ platform and portfolio

Jun 25, 2025, 8:00 AM EDT - 6 months ago

Evaxion expands R&D pipeline with new vaccine program targeting Group A Streptococcus

Jun 3, 2025, 9:15 AM EDT - 7 months ago

Evaxion receives grant funding to design new polio vaccine

May 27, 2025, 10:43 AM EDT - 7 months ago

Evaxion Biotech A/S (EVAX) Q1 2025 Earnings Conference Call Transcript

May 27, 2025, 7:30 AM EDT - 7 months ago

Evaxion announces business update and first quarter 2025 financial results

May 26, 2025, 8:47 AM EDT - 7 months ago

Evaxion: Progress Unrecognized By Market And A Catalyst-Full 2025

May 23, 2025, 8:00 AM EDT - 7 months ago

Evaxion to announce business update and first quarter 2025 financial results on May 27, 2025

May 22, 2025, 8:00 AM EDT - 7 months ago

Evaxion doses first patient in extension of phase 2 trial exploring the full potential of AI-designed personalized cancer vaccine EVX-01

Apr 28, 2025, 8:00 AM EDT - 8 months ago

80% of the EVX-01 vaccine targets trigger a tumor-reactive immune response - Evaxion presents striking EVX-01 data at the AACR Annual meeting

Apr 10, 2025, 8:00 AM EDT - 9 months ago

Evaxion to present at World Vaccine Congress

Apr 1, 2025, 11:21 AM EDT - 9 months ago

Evaxion Biotech A/S (EVAX) Q4 2024 Earnings Call Transcript

Mar 27, 2025, 8:00 AM EDT - 9 months ago

Evaxion to announce business update and full year 2024 financial results on April 1, 2025

Mar 25, 2025, 4:30 PM EDT - 9 months ago

Evaxion to present new phase 2 data for AI-designed personalized cancer vaccine EVX-01 at AACR Annual Meeting

Feb 25, 2025, 8:00 AM EST - 10 months ago

Evaxion extends phase 2 trial with personalized cancer vaccine EVX-01 to further enhance clinical data package

Jan 31, 2025, 4:05 PM EST - 11 months ago

Evaxion announces closing of $10.8 million public offering

Jan 30, 2025, 8:00 AM EST - 11 months ago

Evaxion announces pricing of $10.8 million public offering

Jan 28, 2025, 8:15 AM EST - 11 months ago

Evaxion granted 180-day compliance extension by Nasdaq as it restores equity above minimum requirement

Jan 14, 2025, 4:05 PM EST - 1 year ago

Evaxion announces completion of ADS ratio change

Jan 10, 2025, 8:00 AM EST - 1 year ago

Evaxion announces extension to January 14, 2025, of plan to implement ADS ratio change

Dec 30, 2024, 8:00 AM EST - 1 year ago

Evaxion announces plan to implement ADS ratio change

Nov 12, 2024, 8:00 AM EST - 1 year ago

Evaxion announces positive preclinical data for cytomegalovirus (CMV) vaccine program EVX-V1

Oct 31, 2024, 8:00 AM EDT - 1 year ago

Evaxion announces business update and third quarter 2024 financial results

Oct 28, 2024, 8:00 AM EDT - 1 year ago

Evaxion to announce business update and third quarter 2024 financial results on October 31

Oct 9, 2024, 8:00 AM EDT - 1 year ago

Strong validation of Evaxion's AI-Immunology™ platform in multiple clinical trials

Oct 3, 2024, 8:00 AM EDT - 1 year ago

Recent clinical data confirms significantly improved predictive power of Evaxion's AI-Immunology™ platform

Sep 26, 2024, 10:53 AM EDT - 1 year ago

Evaxion Biotech Partners With Merck To Expand Vaccine Development

MRK

Sep 26, 2024, 7:30 AM EDT - 1 year ago

Evaxion significantly expands vaccine development collaboration with MSD

GrowthGuruV3 Dec. 25 at 12:50 PM

0 · Reply

asbpame Dec. 24 at 6:03 PM

$EVAX Merry Christmas to the bulls and....ok, for the bears, also, because is Christmas

0 · Reply

asbpame Dec. 24 at 5:24 PM

$EVAX i hope Santa push the price to green in rhe last half hour...

0 · Reply

asbpame Dec. 24 at 5:04 PM

$EVAX looking at the last 1 hour bar we were about to go up, if the lines crossed gave a buy signal but the mfkers in the last minute send it down no to cross to avoid crossing upwards..

0 · Reply

CobaltCalls Dec. 24 at 11:50 AM

$EVAX Future price discovery depends on how execution velocity aligns with stated operational milestones. Execution slippage remains the dominant downside risk.

1 · Reply

asbpame Dec. 23 at 6:26 PM

$EVAX oversold

0 · Reply

baldaldo Dec. 23 at 5:48 PM

$EVAX Well crap. Now I'm wondering if the cancer vaccine is all fluff, too...

0 · Reply

Whtmtn Dec. 23 at 3:25 PM

$EVAX Déjà vu with Helen. Same sht different company.

0 · Reply

asbpame Dec. 19 at 8:37 PM

$EVAX hi guys , what fuck'n news were sent that had afected the price today? I didn't get...

2 · Reply

Manwiththeplan Dec. 19 at 8:26 PM

$EVAX well the news doesnt change much for me. The same potential

2 · Reply

asbpame Dec. 19 at 7:01 PM

$EVAX extremely oversold in RSI

0 · Reply

Manwiththeplan Dec. 19 at 2:57 PM

$EVAX damn this is not the kind of news i was waiting for

0 · Reply

Lenni_D Dec. 19 at 12:40 PM

$EVAX Previous clown CEO even talked about how MSD pushed out a potential partner for the Gonorrhea asset where the final terms had been agreed to. Turns out to be a horrible idea and even if they had exercised the option what a stupid thing to say that MSD as a major shareholder is able to snatch up a fully negotiated deal in front of other potential partners. It’s already somewhat problematic that MSD is a major shareholder in terms of bringing in other big Pharma.

1 · Reply

Lenni_D Dec. 19 at 12:23 PM

$EVAX Looks like another disappointing year for Evaxion deals. 2024 the estimate was for 14 m $ - actual was a 3 m $ MSD option deal. I guess you could say that the 7.5 m option exercise in 2025 should count as part of the 2024 deal which brings 2024 to 10.5 m. 2025 estimates was not for a certain amount but for 2 new deals. So far they have made no deals but count the option exercise as a 2025 deal which it is not. I really hope this early PR means there is a new deal being announced later. EVAX has very impressive preclinical and clinical data but they suck at making deals. Which is why they hired the previous clown CEO who was supposed to strengthen the deal side. And it’s why they fired him after failing miserably and now has a new CEO.

1 · Reply

Stmkr Dec. 19 at 12:08 PM

$EVAX Dissapointing and suprising. Curious why MSD not interested. Doesnt look good for the candidate

1 · Reply

Lenni_D Dec. 19 at 12:05 PM

$EVAX https://evaxion.ai/investors/press-releases/?press_release_id=10836 Ouch! MSD will not exercise its option for Evaxion’s Gonorrhea vaccine candidate EVX-B2

0 · Reply

Manwiththeplan Dec. 17 at 12:53 PM

$EVAX i am in south africa with my familiy. I think of buying a holiday house here. I just need $EVAX to go to $15 this week

2 · Reply

PnLTagView_839 Dec. 17 at 11:08 AM

$EVAX microcap biotech hanging near lows, any upside is pure asymmetry once a catalyst brings real liquidity

0 · Reply

Stock__Hunter Dec. 15 at 3:58 PM

$EVAX trip top and couldnt break, now falling back down

1 · Reply

Stock__Hunter Dec. 11 at 5:22 PM

$EVAX

0 · Reply

SanJose2 Dec. 11 at 2:47 PM

$EVAX

0 · Reply

Sidoti Dec. 11 at 2:41 PM

The Evaxion ($EVAX) Management Team presented today at the Sidoti Year End Virtual Conference. Watch the replay here: https://sidoti.zoom.us/webinar/register/WN_uUq3hMPNSUSPuJlDQtjcqw

1 · Reply

Market Cap	2.30M
Revenue (ttm)	3.34M
Net Income (ttm)	-10.57M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-316.47%
Debt to Equity Ratio	-4.95

Volume	57,600
Avg Vol	68,002
Day's Range	N/A - N/A
Shares Out	1.40M
Stochastic %K	76%
Beta	-0.24
Analysts	Strong Sell
Price Target	$13.25